Natco Pharma Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/b1cmps1f54s5idei0koasczd.pdf

Key Takeaways


CTPR: The New Earnings Driver

Rajeev Nannapaneni: "I'm very excited and I think you'll see a good bump in earnings in the next two quarters from CTPR, that will drive our base business in the next few quarters."

Lenalidomide: The Known Unknown

Rajesh Chebiyam: "I think considering the nature of our business and the way we do things; I think you have to take a 12-month earnings."

Subsidiaries: The Silent Profit Engine


US Pipeline: Betting on Blockbusters

Rajesh Chebiyam: "I still believe that we need to deliver at least three, four very large FTF type of products or complex generic type of products to be competitive in the US. ... if we're able to deliver another three, four products like Revlimid in the next decade, I think your whole decade is set."

Domestic Pharma: Steady, With Acquisition Ambition

Rajeev Nannapaneni: "I think the challenge that we have is, we only cover specialty doctors, we don't cover general physicians and larger segments of doctors. So, I think that's what I believe in either we do it through increase of field force, or we do it through an acquisition."

Agro Sciences: Beyond CTPR

Rajesh Chebiyam: "When you're in a very aggressive generic company, you can't do innovator alliances, you can't have it both ways, you can't say that I will go up to your patent, but I will also supply product to you, it doesn't work like that. You have to choose one camp."

Guidance & Commitments

CommitmentSpecificsTimeline
CTPR sales rampSales begin and drive base business earningsStarting Q3 FY23 (December quarter), peak in Q1 FY24 (June quarter)
Lenalidomide US profit shareMinimal in Q3; fresh quantity and full profit share resumeQ4 FY23 and Q1 FY24
Subsidiary revenue growthCanada + Brazil combined business to rise from ₹0.9–1.0 cr to ₹1.5 crNext two quarters
US ANDA FTF confirmationFTF status on two recent filings to be known upon ANDA acceptanceNext few weeks (acceptance takes 60–90 days)
Generic Pomalyst US launchLaunch per settlement termsApproximately two years from now
Small domestic acquisitionClose a transaction for an asset with ~₹100–150 cr in salesNext few months
Lenalidomide volume expansionAnnual reset cycle adds volumeAround March 1 each year
CTPR double-bench rulingVerdict on the appeal against the single-bench orderOrder reserved; timeline unspecified

Key Metrics

MetricQ2 FY23
Consolidated total revenue₹452.6 cr, approximately 9% growth YoY from ₹415.2 cr
Consolidated net profit₹56.8 cr, against ₹65.1 cr in same period last year
Lenalidomide US export profit shareMinimal, as communicated in prior calls
Oncology domestic sale₹55 cr
Canada subsidiary revenue (last quarter)₹0.65 cr
Brazil subsidiary revenue (last quarter)a little less than ₹0.3 cr
Canada and Brazil combined business₹0.9 to 1 cr, expected to increase to ₹1.5 cr in next two quarters
Standalone inventory₹665 cr as of 30th September 2022, of which ₹110 cr is agro inventory
Cash and cash equivalents₹1,000 cr as of end of Q2
Borrowings₹82 cr, of which ₹50 cr is foreign bill discount associate
CTPR molecule market size (plain plus combination)a little less than ₹3,000 cr (₹2,000 cr plain, ₹800 cr combination)
CTPR expected revenue split50% to 60% or more from B2B, about 35% to 40% from B2C
CTPR discount on MRPabout 25%, plus additional trade discounts
Domestic business acquisition target size₹100-150 cr worth of sale
Dividend payout planabout 20% to 25% of cash flow